NEULANDLABPharmaceuticals
Neuland Laboratories Ltd — PE Ratio & Valuation Analysis
₹12027.00
-1.94%
Current P/E108.36xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E52.1x107.9% above avg
⚠️
241.1% Premium to Industry
NEULANDLAB P/E 108.36x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹202.74 | ₹15175 | 74.8x |
| 2024 | ₹233.89 | ₹13724 | 58.7x |
| 2023 | ₹127.45 | ₹5291 | 41.5x |
| 2022 | ₹49.74 | ₹1667 | 33.5x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Neuland Laboratories Ltd Valuation
Neuland Laboratories Ltd (NEULANDLAB) currently trades at 108.36x earnings. The Pharmaceuticals sector average PE is 31.77x. NEULANDLAB commands a premium, reflecting high growth expectations. Historically, NEULANDLAB has traded at an average PE of 52.1x — it is currently above that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
14.83%
Dividend Yield
0.07%
More on Neuland Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.